Is larotrectinib available in China? Good buy?

Larotinib can block the signaling pathway mediated by TRK and inhibit the activity of TRK to block the growth and spread of tumor cells. Its accessibility in the Chinese market is crucial for NTRK gene fusion-positive tumor patients. This article will introduce in detail the launch progress, purchase channels and medical insurance reimbursement status of this drug in China, and provide practical guidance for patients.

Is larotinib available in China

has been officially approved by Chinese regulatory authorities, bringing new treatment hope to patients with specific genetic types of tumors.

Domestic Approval Status

On April 13, 2022, the China National Medical Products Administration officially approved the marketing of larotrectinib, with the trade name Vitacai. The approval was based on global clinical trial data, including research results on Chinese patients.

Scope of Indications

The domestically approved indications are adult and pediatric patients with NTRK gene fusion-positive solid tumors. It is the first targeted therapy drug approved in China that does not distinguish between tumor sources.

Dosage form specifications

The Chinese market currently provides capsule dosage forms of 25 mg and 100 mg. For pediatric patients, a 20 mg/ml oral solution dosage form has also been specially launched.

After learning about the listing situation, patients are most concerned about the actual purchasing channels and convenience. The relevant situation will be introduced in detail below.

Is larotrectinib easy to buy?

As a specially managed drug, the purchase channels for larotrectinib are relatively limited but are gradually expanding.

Hospital pharmacy supply

Many large hospital oncology pharmacies in China are equipped with this drug, and patients need to bring the NTRK gene test report and a prescription from a specialist to purchase it.

Designated pharmacy channels

Some urban specialty drug pharmacies provide larotrectinib purchase services. These pharmacies are usually equipped with professional pharmacists who can provide medication guidance, but an appointment is required in advance.

Purchase process requirements

Complete medical records, original genetic test reports and physician prescriptions are required when purchasing. Some hospitals require patients to establish treatment files and conduct regular follow-up visits.

In addition to purchasing channels, medical insurance reimbursement policies directly affect patients’ financial burden. The current medical insurance status of this drug will be analyzed below.

Is larotrectinib included in the national medical insurance list?

Larotinib has been included in the national medical insurance catalog, which has greatly reduced the financial pressure on patients.

Medical insurance inclusion time

The drug will be officially included in the national medical insurance drug catalog on January 1, 2023, and the reimbursement scope covers all approved indications.

Reimbursement conditions

Patients must provide a positive test report for NTRK gene fusion and be diagnosed by a specialist at a second-level hospital or above. Medical insurance filing procedures must be completed before reimbursement.

Reimbursement ratio

There may be a difference between the reimbursement ratio of urban employees’ medical insurance and the reimbursement ratio of urban and rural residents. After reimbursement by medical insurance, patients’ monthly out-of-pocket expenses can be reduced.

Larotinib is a prescription drug and must be used under the guidance of a doctor. Patients should purchase it through formal channels and undergo regular genetic testing and efficacy evaluation. If adverse reactions occur during treatment, you should seek medical advice promptly to adjust the medication regimen.